Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the last few shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely marketing picture in the Uptick Newswire employment interview that I came away with a bad viewpoint of the company.

Irony of irony, the poor opinion of mine of the business has grown steadily, although the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of the expertise as well as associated intellectual property from Progenics to CytoDyn, and also approximately twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) and the first new drug program approval ($5 million), and even royalty payments of five % of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and many indications, it’s this single treatments as well as a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple delivering presentations in addition to multiple publications.

Could it all be smoke and mirrors? That’s a question I have been asking myself with the really start of the interest of mine in this particular company. Judging by the multiples of thousands of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *